An observational study in Cardiovascular Diseases, Metabolic Disorders and Ageing and Geriatric Health, sponsored by Jinwei Tian. Recruiting at 1 site in China. Open to participants aged 60 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-20.
Sponsored by Jinwei Tian · Observational
The Chinese Migrant Population Health Cohort is a prospective, multi-center study jointly initiated by Professor Yong Ji, President of Harbin Medical University, and Academician Guoqiang Chen, President of Hainan Medical University, in collaboration with regional partners. It targets older adults (≥60 years) who engage in seasonal migration between cold (Heilongjiang) and tropical (Hainan) regions. The primary objective is to investigate cardiovascular and metabolic disease risks, underlying biological and environmental mechanisms, and effective preventive strategies in this unique population.
Participants are recruited from both origin and destination sites and undergo standardized baseline assessments, including questionnaires, physical examinations, medical imaging, biospecimen collection (blood, stool, hair, nails), and environmental exposure monitoring. Longitudinal follow-up includes periodic reassessments, remote monitoring, and data linkage with hospital information systems to capture health outcomes.
The study aims to:
Define migration-related health risk profiles and disease phenotypes.
Elucidate biological and environmental mechanisms influencing disease onset and progression.
Develop AI-driven risk prediction models and evaluate targeted interventions through nested randomized controlled trials.
Translate findings into clinical guidelines and scalable cross-regional health management models.
This is the first cohort in China to systematically investigate the health impacts of seasonal migration in older adults. By integrating epidemiology, multi-omics, environmental data, and health policy translation, the study seeks to improve continuity of care, strengthen climate adaptation, and promote healthy ageing.
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's planned enrollment of 26,000 is above the median of 573 across 1,485 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Jinwei Tian is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will enroll community-dwelling adults aged ≥60 years from Harbin (cold region) and Hainan (tropical region), China. Four groups will be included: 1. Winter Migrant Group: \~5,000 Harbin residents who habitually migrate to Hainan during the cold season for ≥2 months each time, with ≥2 consecutive years of such migration and plans to continue; 2. Summer Migrant Group: \~1,000 Hainan residents who habitually migrate to Harbin during the hot season for ≥2 months, with similar migration history and plans; 3. Cold-Region Resident Group: \~10,000 Harbin residents, including matched controls for migrant groups and randomly selected residents, with no >2 months residence outside Harbin in the past 5 years; 4. Tropical-Region Resident Group: \~10,000 Hainan residents with similar matching criteria and residency requirements.
All participants must be able to communicate, perform daily activities independently, consent to long-term follow-up, and provide biospecimens.
Exclusion Criteria:
No Intervention
Other: No intervention
No Intervention
Other: No intervention
no Intervention
Other: No intervention
no Intervention
Other: No intervention
no intervention
Number of Participants Experiencing First Major Cardiovascular Event
First occurrence of myocardial infarction, stroke (ischemic or hemorrhagic), or cardiovascular death, confirmed through hospital records, death registries, and adjudication committee review.
Time frame: Up to 5 years from baseline
Number of Participants with New-Onset Metabolic Disorders
New-onset type 2 diabetes mellitus, dyslipidemia, or obesity as defined by standard clinical and laboratory criteria.
Time frame: Up to 5 years from baseline
Number of Deaths from Any Cause
Death from any cause, verified through official death certificates and hospital records.
Time frame: Up to 5 years from baseline
Changes in Cardiometabolic Risk Factors
Longitudinal changes in blood pressure, fasting glucose, HbA1c, lipid profile, BMI, waist circumference, and body composition.
Time frame: Baseline, 2 years, 4 years
Change in EQ-5D Quality of Life Score from Baseline
Changes in validated quality-of-life scales (e.g., EQ-5D).
Time frame: Baseline, 2 years, 4 years
Change in Cognitive Function Score (MoCA) from Baseline
Mean change in Montreal Cognitive Assessment score.
Time frame: Baseline, 2 years, 4 years
Change in Carotid Intima-Media Thickness from Baseline
Mean change (mm) measured by carotid ultrasound.
Time frame: Baseline and follow-up imaging
Change in Coronary Artery Calcium Score from Baseline
Mean change in Agatston score by CT angiography.
Time frame: Baseline and follow-up imaging
Change in Plasma Metabolite Levels from Baseline
Relative or absolute change in concentrations of targeted metabolites identified through mass spectrometry.
Time frame: Baseline and follow-up biospecimen analyses
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jinwei Tian